
Vertex Pharmaceuticals Incorporated: updates and filings
Price
$538.60
November 13, 2026Market cap $137B
What Ploutos Investor adds for Vertex Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 2, 2026next Feb 3, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
September 2026
August 2026
July 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 3, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 2, 2026Results of operationsForm8-K
- Oct 20, 2026Officer or director changeForm8-K
- Sep 1, 2026Officer or director changeForm8-K
- Aug 4, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 3, 2026Results of operationsForm8-K
- Jul 7, 2026Material agreement entered, Regulation FD disclosure, other material eventsForm8-K
- May 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 13, 2026FilingFormS-8 POS
- May 13, 2026FilingFormS-8 POS
- May 13, 2026FilingFormS-8 POS
- May 13, 2026FilingFormS-8 POS
- May 13, 2026FilingFormS-8 POS
- May 13, 2026FilingFormS-8 POS
- May 13, 2026FilingFormS-8 POS
- May 13, 2026Shares registered for employeesFormS-8
- May 13, 2026Officer or director change, shareholder voteForm8-K
- May 5, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 4, 2026Results of operationsForm8-K
- Apr 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Additional annual meeting materialFormDEFA14A
- Apr 29, 2026Officer or director changeForm8-K
- Apr 14, 2026Letter from the SECFormUPLOAD
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 3, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 2, 2026 | 8-K | Results of operations | Document |
| Oct 20, 2026 | 8-K | Officer or director change | Document |
| Sep 1, 2026 | 8-K | Officer or director change | Document |
| Aug 4, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 3, 2026 | 8-K | Results of operations | Document |
| Jul 7, 2026 | 8-K | Material agreement entered, Regulation FD disclosure, other material events | Document |
| May 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 13, 2026 | S-8 POS | Filing | Document |
| May 13, 2026 | S-8 POS | Filing | Document |
| May 13, 2026 | S-8 POS | Filing | Document |
| May 13, 2026 | S-8 POS | Filing | Document |
| May 13, 2026 | S-8 POS | Filing | Document |
| May 13, 2026 | S-8 POS | Filing | Document |
| May 13, 2026 | S-8 POS | Filing | Document |
| May 13, 2026 | S-8 | Shares registered for employees | Document |
| May 13, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 5, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 4, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 29, 2026 | 8-K | Officer or director change | Document |
| Apr 14, 2026 | UPLOAD | Letter from the SEC | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 15, 1995. Of its note and share prospectuses (424B, FWP), the newest 40 of 47.
The full analysis
What do Vertex Pharmaceuticals's filings show?
The filings are where every one of Vertex Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.